Grzeszczuk Anna, Wandalowicz Alicja Danuta, Jaroszewicz Jerzy, Flisiak Robert
Department of Infectious Diseases and Hepatology, Medical University of Bialystok, Bialystok, Poland.
Hepat Mon. 2015 Jul 22;15(7):e27740. doi: 10.5812/hepatmon.27740v2. eCollection 2015 Jul.
HIV/HCV co-infection predisposes to accelerated liver damage and increased both liver-related and unrelated morbidity and mortality in patients with HIV infection.
The aim of this study was to evaluate the prevalence of HCV infection, seropositivity, risk factors and genotype distribution among treated HIV positive patients. Furthermore, the occurrence and causes of deaths were analyzed.
Adult HIV-1 infected patients, with at least one antiHCV result, treated in one of Polish HIV/AIDS reference centers, participated in this cross-sectional study.
Four hundred and fifty seven patients with a median age of 38 years (ranged 23 - 72), and predominantly male (76.6%) were enrolled in the study. Anti-HCV antibodies were detected in 325 individuals (71.1%). HCV RNA was detected in 207 of the 233 patients tested (88%). The HCV genotype analysis (n = 193) demonstrated almost equal distribution with slight genotype 1 domination as 37.3%, mainly 1b, followed by genotypes 3 as 32.1% and 4 as 30.6%. No association was found between HCV genotype and route of HIV acquisition. In univariate analysis, higher HCV seropositivity was related to male sex, intravenous drug use (IDU), mode of HIV transmission, history of drug and alcohol abuse and imprisonment. In multivariate analysis, only being injection drug user (P = 0.0001), imprisonment (P = 0.310) and younger age at the HIV diagnosis per each year (P = 0.025) were identified as risk factors for HCV infection. Sixty three deaths were reported; no association was found between HCV seropositivity and death prevalence.
HIV/HCV co-infection is an important medical problem in North-Eastern Poland. A history of incarceration and younger age at HIV diagnosis were additional to IDU risk factors for HCV seropositivity in this cohort.
HIV/HCV合并感染易导致肝脏损害加速,增加HIV感染患者肝脏相关及非肝脏相关的发病率和死亡率。
本研究旨在评估接受治疗的HIV阳性患者中HCV感染的患病率、血清阳性率、危险因素及基因型分布。此外,还分析了死亡的发生情况及原因。
在波兰的一个HIV/AIDS参考中心接受治疗的成年HIV-1感染患者,至少有一次抗HCV检测结果,参与了这项横断面研究。
457名患者纳入研究,中位年龄38岁(范围23 - 72岁),男性居多(76.6%)。325例(71.1%)检测出抗HCV抗体。在233例接受检测的患者中,207例(88%)检测出HCV RNA。HCV基因型分析(n = 193)显示分布几乎相等,基因型1略占优势,为37.3%,主要是1b型,其次是基因型3,占32.1%,基因型4占30.6%。未发现HCV基因型与HIV感染途径之间存在关联。单因素分析中,较高的HCV血清阳性率与男性、静脉注射吸毒(IDU)、HIV传播方式、药物和酒精滥用史及监禁史有关。多因素分析中,仅注射吸毒者(P = 0.0001)、监禁(P = 0.310)及HIV诊断时每年年龄较小(P = 0.025)被确定为HCV感染的危险因素。报告了63例死亡病例;未发现HCV血清阳性率与死亡患病率之间存在关联。
HIV/HCV合并感染是波兰东北部一个重要的医学问题。在该队列中,监禁史和HIV诊断时年龄较小是除IDU之外HCV血清阳性的危险因素。